Tag: currency

Washington, DC, June 21, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/06/21/week-22-of-americas-rise-to-greatness-under-president-trumps-leadership/

Lotus Asia has introduced a broad range of fast payout options to allow players to access withdrawals faster. This aligns with the growing demand for quicker, more flexible payout options.

Frumzi Casino Has Recently Expanded Its Catalogue of Live Dealer Games, In Order to Become One of the Top Choice Amongst Real Money Online Casinos in Canada for Game Variety

One phone, one contract, and you can easily start your journey to increase the value of your crypto assets

The price of XRP has fluctuated violently, rising to $2.20 before falling back to about $2.15, affected by market's risk aversion. At the same time, the stablecoin RLUSD launched by Ripple was approved by Dubai, which strengthened its confidence in global expansion; a Chinese institution plans to invest $300 million in the purchase of XRP, highlighting its rising appeal. In addition, the dispute between Trump and Musk has also brought volatility to the market. XRP is still hovering around the key support level of $2.00, and the future direction depends on legal progress and ETF approval.

Transaction in Own Shares

London, United Kingdom, June 20, 2025 (GLOBE NEWSWIRE) -- As the global demand for passive income from cryptocurrencies surges, Topnotch Crypto cloud mining platform stands out, building a new channel to crypto assets for users with its core advantages of "zero threshold, low risk, and high transparency".

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.